Comparison of TP53 mutations identified by oligonucleotide microarray and conventional DNA sequence analysis.

As the rate of gene discovery accelerates, more efficient methods are needed to analyze genes in human tissues. To assess the efficiency, sensitivity, and specificity of different methods, alterations of TP53 were independently evaluated in 108 ovarian tumors by conventional DNA sequence analysis and oligonucleotide microarray (p53 GeneChip). All mutations identified by oligonucleotide microarray and all disagreements with conventional gel-based DNA sequence analysis were confirmed by re-analysis with manual and automated dideoxy DNA sequencing. A total of 77 ovarian cancers were identified as having TP53 mutations by one of the two approaches, 71 by microarray and 63 by gel-based DNA sequence analysis. The same mutation was identified in 57 ovarian cancers, and the same wild type TP53 sequence was observed in 31 ovarian cancers by both methods, for a concordance rate of 81%. Among the mutation analyses discordant by these methods for TP53 sequence were 14 cases identified as mutated by microarray but not by conventional DNA sequence analysis and 6 cases identified as mutated by conventional DNA sequence analysis but not by microarray. Overall, the oligonucleotide microarray demonstrated a 94% accuracy rate, a 92% sensitivity, and an 100% specificity. Conventional DNA sequence analysis demonstrated an 87% accuracy rate, 82% sensitivity, and a 100% specificity. Patients with TP53 mutations had significantly shorter overall survival than those with no mutation (P = 0.02). Women with mutations in loop2, loop3, or the loop-sheet-helix domain had shorter survival than women with other mutations or women with no mutations (P = 0.01). Although further refinement would be helpful to improve the detection of certain types of TPS3 alterations, oligonucleotide microarrays were shown to be a powerful and effective tool for TP53 mutation detection.

[1]  A. Thor,et al.  p53 gene analysis of ovarian borderline tumors and stage I carcinomas. , 1995, Human pathology.

[2]  Thierry Soussi,et al.  P53 Gene Mutation: Software and Database , 1998, Nucleic Acids Res..

[3]  S. P. Fodor,et al.  Evolutionary sequence comparisons using high-density oligonucleotide arrays , 1998, Nature Genetics.

[4]  R. Kreienberg,et al.  p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. , 1996, British Journal of Cancer.

[5]  E. Southern,et al.  DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. , 1996, Trends in genetics : TIG.

[6]  B. Karlan,et al.  DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.

[7]  J. Hacia.  Resequencing and mutational analysis using oligonucleotide microarrays , 1999, Nature Genetics.

[8]  R. Kreienberg,et al.  p53 mutations and expression in ovarian cancers: correlation with overall survival. , 1999, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[9]  A. Sood,et al.  An abundance of p53 null mutations in ovarian carcinoma. , 1996, Oncogene.

[10]  R W Wallace.  DNA on a chip: serving up the genome for diagnostics and research. , 1997, Molecular medicine today.

[11]  S. Hirohashi,et al.  High Incidence of p53 Gene Mutation in Human Ovarian Cancer and Its Association with Nuclear Accumulation of p53 Protein and Tumor DNA Aneuploidy , 1992, Japanese journal of cancer research : Gann.

[12]  J. Jen,et al.  Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. P. Fodor,et al.  High density synthetic oligonucleotide arrays , 1999, Nature Genetics.

[14]  Wojciech Makalowski,et al.  Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features , 1999, Oncogene.

[15]  A. Thor,et al.  p53 gene mutations and protein accumulation in human ovarian cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[16]  E. Southern,et al.  Molecular interactions on microarrays , 1999, Nature Genetics.

[17]  C. Arrowsmith,et al.  New insights into p53 function from structural studies. , 1996, Oncogene.

[18]  M. Kubbutat,et al.  Keeping an old friend under control: regulation of p53 stability. , 1998, Molecular medicine today.

[19]  S. P. Fodor,et al.  Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two–colour fluorescence analysis , 1996, Nature Genetics.

[20]  R. Cotton,et al.  Slowly but surely towards better scanning for mutations. , 1997, Trends in genetics : TIG.

[21]  Thierry Soussi,et al.  P53 Gene Mutation: Software and Database , 1996, Nucleic Acids Res..

[22]  W P Bennett,et al.  Molecular epidemiology of human cancer risk: gene–environment interactions and p53 mutation spectrum in human lung cancer , 1999, The Journal of pathology.

[23]  Patricia Rodriguez-Tomé,et al.  IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools , 1998, Nucleic Acids Res..

[24]  R. Kreienberg,et al.  Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. , 1998, Oncology reports.